Mirae Asset Global Investments
CTMX icon

Mirae Asset Global Investments’s CytomX Therapeutics CTMX Stock Holding History

Mirae Asset Global Investments’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$36.5K Buy
9,736
+898
+10% +$3.43K ﹤0.01% 1410
2026
Q1 		$41.5K Buy
8,838
+605
+7% +$3.07K ﹤0.01% 1325
2025
Q4 		$35.1K Buy
+8,233
New +$31.3K ﹤0.01% 1468

Other funds holding CTMX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Mirae Asset Global Investments's CTMX Position: Q2 2026 in Review

Mirae Asset Global Investments increased its CytomX Therapeutics (CTMX) stake by 10% in Q2 2026, buying an estimated $3.43K and bringing the position to 9,736 shares worth $36.5K. The position accounts for ﹤0.01% of the portfolio, ranked #1410.

Mirae Asset Global Investments first reported a position in CTMX in Q4 2025 and has held it in 3 quarters since. The position peaked at $41.5K in Q1 2026. 178 funds tracked by Wall St. Rank hold CTMX as of Q2 2026.

  • Mirae Asset Global Investments held 9,736 shares of CytomX Therapeutics worth $36.5K as of Q2 2026.
  • Mirae Asset Global Investments bought 898 CytomX Therapeutics shares in Q2 2026, an estimated $3.43K.
  • CytomX Therapeutics made up ﹤0.01% of Mirae Asset Global Investments's portfolio in Q2 2026, its #1410 holding.
  • Mirae Asset Global Investments first reported a position in CytomX Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Mirae Asset Global Investments's CytomX Therapeutics position peaked at $41.5K in Q1 2026.
  • 178 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2026.

Based on Mirae Asset Global Investments's 13F filing for Q2 2026, filed 22 Jul 2026.